How do oncologists rate reimbursement requests for off-label treatments?

The FOPH is currently evaluating Articles 71a-71b KVV (Off Label Use)

How do oncologists rate reimbursement requests for off-label treatments?

The FOPH is currently evaluating Articles 71a-71b KVV (Off Label Use)

For its part, KLS has investigated the satisfaction of oncologists with the reimbursement applications for off-label treatments. In his article in the Swiss Cancer Bulletin No. 3/2019, author Dr Dimitri Kohler (KLS) examines the various aspects of the procedure in connection with reimbursement applications for off-label treatments. The KLS survey shows that there are regional inequalities. The oncologists surveyed unanimously confirmed unequal access to treatment and differences in waiting times for a response from health insurance. The evaluation of the applications of the Lucerne Cantonal Hospital (LUKS) provides a comprehensive overview of the situation and confirms the scheduling problems.

The article from September 2019 in the Swiss Cancer Bulletin can be found here (p. 243-249).

The FOPH's current evaluation of Articles 71a-71b KVV is intended to examine the status of implementation of the changes from the partial KVV revision of 1 February 2017 and to assess the appropriateness and effectiveness of the measures. Any potential for optimisation with regard to regulation and/or implementation shall be identified.

An overview of current and completed FOPH evaluation studies in the field of health and accident insurance can be found here.

All News